Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) EBT: 2014-2025

Historic EBT for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$42.3 million.

  • KalVista Pharmaceuticals' EBT rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of -$180.1 million for FY2025, which is 42.17% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' EBT is -$42.3 million, which was down 4.51% from -$40.4 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' EBT registered a high of -$29.0 million during Q1 2024, and its lowest value of -$44.6 million during Q2 2024.
  • Over the past 2 years, KalVista Pharmaceuticals' median EBT value was -$41.4 million (recorded in 2024), while the average stood at -$39.1 million.
  • Data for KalVista Pharmaceuticals' EBT shows a peak YoY rose of 5.34% (in 2025) over the last 5 years.
  • Over the past 2 years, KalVista Pharmaceuticals' EBT (Quarterly) stood at -$40.4 million in 2024, then increased by 5.34% to -$42.3 million in 2025.
  • Its EBT stands at -$42.3 million for Q2 2025, versus -$40.4 million for Q3 2024 and -$44.6 million for Q2 2024.